AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18847151 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (nebulized fluticasone and intravenous methylprednisolone)
Number of subjects: 73
Study 18847151 — intervention group
Group type: EXPERIMENTAL
Intervention: Flixotide treatment arm
Number of subjects: 73
Study 18847151 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 73
Study 15971087 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 35
Study 15971087 — intervention group
Group type: COMPARATOR
Intervention: Tramadol + Midazolam (TM)
Number of subjects: 35
Study 12962188 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdebrider
Number of subjects: 24
Study 12962188 — intervention group
Group type: COMPARATOR
Intervention: Conventional instruments
Number of subjects: 24
Study 10599358 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg/day)
Number of subjects: 41
Study 10599358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 8747045 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI)
Number of subjects: 43
Study 8747045 — intervention group
Group type: COMPARATOR
Intervention: Intracervical insemination (ICI)
Number of subjects: 43
Study 2106256 — intervention group
Group type: EXPERIMENTAL
Intervention: [1-13C]acetate infusion
Number of subjects: 10
Study 2106256 — intervention group
Group type: EXPERIMENTAL
Intervention: [2-13C]acetate infusion
Number of subjects: 10
Study 2106256 — intervention group
Group type: EXPERIMENTAL
Intervention: [1-13C]acetate infusion during exogenous glucose infusion
Number of subjects: 10
Study 2106256 — intervention group
Group type: EXPERIMENTAL
Intervention: [2-13C]acetate infusion during exogenous glucose infusion
Number of subjects: 10
Study 2106256 — intervention group
Group type: EXPERIMENTAL
Intervention: [1-14C]acetate infusion
Number of subjects: 10
Study 7030373 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nifedipine and propranolol
Number of subjects: 25
Study 7030373 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (50% dosage reduction)
Number of subjects: 25
Study 30789934 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational patient education including motivational communication techniques and repeated training until correct administration.
Number of subjects: 91
Study 30789934 — intervention group
Group type: COMPARATOR
Intervention: Standard feedback on erroneous administration steps without further assessment or reinforced training.
Number of subjects: 91
Study 30193275 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate reduction to 0.4 mg of nicotine per gram of tobacco cigarettes
Number of subjects: 1250
Study 30193275 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual reduction from 15.5 mg to 0.4 mg of nicotine per gram of tobacco cigarettes
Number of subjects: 1250
Study 30193275 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintenance on 15.5 mg of nicotine per gram of tobacco cigarettes)
Number of subjects: 1250
Study 26797774 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose betahistine (2 × 24 mg daily)
Number of subjects: 221
Study 26797774 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose betahistine (3 × 48 mg daily)
Number of subjects: 221
Study 26797774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study 26797774 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 221
Study 24060491 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm cranking exercise (12-week program, 3 sessions per week)
Number of subjects: 17
Study 24060491 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 17
Study 23018292 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced oscillation technique
Number of subjects: 40
Study 23018292 — intervention group
Group type: COMPARATOR
Intervention: Spirometric parameters
Number of subjects: 40
Study 19811927 — intervention group
Group type: EXPERIMENTAL
Intervention: MHSACP technique
Number of subjects: 50
Study 19811927 — intervention group
Group type: COMPARATOR
Intervention: Moderately hypothermic open heart procedures (control group)
Number of subjects: 50
Study 16890485 — intervention group
Group type: EXPERIMENTAL
Intervention: hGH treatment
Number of subjects: 38
Study 16890485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 16257815 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly alendronate 70 mg oral solution
Number of subjects: 454
Study 16257815 — intervention group
Group type: COMPARATOR
Intervention: Placebo oral solution
Number of subjects: 454
Study 12170051 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60
Study 12170051 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 60
Study 10499773 — intervention group
Group type: EXPERIMENTAL
Intervention: TA 1200 (1200 mg of thioctic acid)
Number of subjects: 65
Study 10499773 — intervention group
Group type: EXPERIMENTAL
Intervention: TA 600 (600 mg of thioctic acid)
Number of subjects: 65
Study 10499773 — intervention group
Group type: COMPARATOR
Intervention: PLA (placebo)
Number of subjects: 65
Study 8688994 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (R)
Number of subjects: 12
Study 8688994 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (T)
Number of subjects: 12
Study 8688994 — intervention group
Group type: EXPERIMENTAL
Intervention: DHECT with metabolites
Number of subjects: 12
Study 1924625 — intervention group
Group type: EXPERIMENTAL
Intervention: Active marijuana (0.8% THC)
Number of subjects: 5
Study 1924625 — intervention group
Group type: EXPERIMENTAL
Intervention: Active marijuana (3.6% THC)
Number of subjects: 5
Study 1924625 — intervention group
Group type: COMPARATOR
Intervention: Placebo marijuana (0.0% THC)
Number of subjects: 5
Study 1924625 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting (24 hr)
Number of subjects: 5
Study 7050949 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclazindol
Number of subjects: 114
Study 7050949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 7050949 — intervention group
Group type: COMPARATOR
Intervention: Ciclazindol vs Placebo
Number of subjects: 114
Study 28810393 — intervention group
Group type: EXPERIMENTAL
Intervention: Dove Evolution commercial
Number of subjects: 287
Study 28810393 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific disclaimer labels
Number of subjects: 287
Study 28810393 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic disclaimer labels
Number of subjects: 287
Study 28810393 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after 2 weeks
Number of subjects: 287
Study 29414757 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace physical exercise (WORK)
Number of subjects: 200
Study 29414757 — intervention group
Group type: COMPARATOR
Intervention: Home-based physical exercise (HOME)
Number of subjects: 200
Study 27227739 — intervention group
Group type: EXPERIMENTAL
Intervention: LPV/r-based ART
Number of subjects: 45
Study 27227739 — intervention group
Group type: EXPERIMENTAL
Intervention: EFV-based ART
Number of subjects: 45
Study 27227739 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ART
Number of subjects: 45
Study 24461499 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin-flap LASIK in thin-cornea group
Number of subjects: 291
Study 24461499 — intervention group
Group type: COMPARATOR
Intervention: Control group (CCT ≥500 μm)
Number of subjects: 291
Study 22794528 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch-up (ABC) intervention
Number of subjects: 0
Study 22794528 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 0
Study 22794528 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (children who were never in foster care)
Number of subjects: 0
Study 21130379 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary Index Score (PIS)
Number of subjects: 65
Study 21130379 — intervention group
Group type: COMPARATOR
Intervention: National Asthma Council Guidelines (NACG)
Number of subjects: 65
Study 17621203 — intervention group
Group type: EXPERIMENTAL
Intervention: Active exercise and education using a cognitive behavioral therapy (CBT) approach, delivered in eight 2-hour group sessions over 6 weeks by physiotherapists.
Number of subjects: 196
Study 17621203 — intervention group
Group type: COMPARATOR
Intervention: Educational booklet and audio-cassette (provided to both intervention and control groups).
Number of subjects: 196
Study 17621203 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who expressed a preference for the intervention.
Number of subjects: 196
Study 15848558 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 g MMF twice a day with SRL
Number of subjects: 27
Study 15848558 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g MMF twice a day with SRL
Number of subjects: 27
Study 15848558 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g MMF twice a day with SRL
Number of subjects: 27
Study 15848558 — intervention group
Group type: COMPARATOR
Intervention: 1 g MMF twice a day with CsA
Number of subjects: 27
Study 12364424 — intervention group
Group type: EXPERIMENTAL
Intervention: RAI plus lithium for 6 days starting on the day of RAI therapy (G2)
Number of subjects: 36
Study 12364424 — intervention group
Group type: EXPERIMENTAL
Intervention: RAI plus lithium for 19 days starting on the day of MMI withdrawal (G3)
Number of subjects: 36
Study 12364424 — intervention group
Group type: COMPARATOR
Intervention: RAI alone (G1)
Number of subjects: 36
Study 12364424 — intervention group
Group type: EXPERIMENTAL
Intervention: RAI plus lithium for 6 days (G2)
Number of subjects: 36
Study 12364424 — intervention group
Group type: EXPERIMENTAL
Intervention: RAI plus lithium for 19 days (G3)
Number of subjects: 36
Study 11803607 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet (LPD) with 0.6 g of protein and 35 kcal/kg/day, recombinant human erythropoietin (rHuEPO) at a dose of 40 U kg/week, and keto acids (KA) 100 mg/kg/day (Group I)
Number of subjects: 105
Study 11803607 — intervention group
Group type: COMPARATOR
Intervention: Low-protein diet (LPD) and recombinant human erythropoietin (rHuEPO) (Group II)
Number of subjects: 105
Study 11803607 — intervention group
Group type: COMPARATOR
Intervention: Low-protein diet (LPD) only (Group III)
Number of subjects: 105
Study 9667297 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0625% bupivacaine with 2.5 microg/ml fentanyl
Number of subjects: 138
Study 9667297 — intervention group
Group type: COMPARATOR
Intervention: 0.125% bupivacaine alone
Number of subjects: 138
Study 7906809 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg aspirin daily
Number of subjects: 9364
Study 7906809 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 9364
Study 2459541 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 120
Study 2459541 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine
Number of subjects: 120
Study 5356547 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 5356547 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylbutazone
Number of subjects: 0
Study 5356547 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid
Number of subjects: 0
Study 5356547 — intervention group
Group type: COMPARATOR
Intervention: Colchicine
Number of subjects: 0
Study 5356547 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 0
Study 5356547 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 0
Study 517720 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethamsylate 1000 mg intravenously before induction of anaesthesia
Number of subjects: 19
Study 517720 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 19
Study 30620642 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO intake algorithm based on CGM trends
Number of subjects: 14
Study 30620642 — intervention group
Group type: COMPARATOR
Intervention: Standard exercise guidelines (0.5 g CHO/kg/h when glucose <8 mmol/L)
Number of subjects: 14
Study 29540273 — intervention group
Group type: COMPARATOR
Intervention: Usual diet and placebo pills (n = 29)
Number of subjects: 88
Study 29540273 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual diet and antioxidant supplements (n = 29)
Number of subjects: 88
Study 29540273 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant-rich foods closely matched to antioxidant content of supplements and placebo (n = 30)
Number of subjects: 88
Study 27334799 — intervention group
Group type: EXPERIMENTAL
Intervention: Bapineuzumab 0.5 mg/kg (noncarriers)
Number of subjects: 694
Study 27334799 — intervention group
Group type: EXPERIMENTAL
Intervention: Bapineuzumab 1.0 mg/kg (noncarriers)
Number of subjects: 694
Study 27334799 — intervention group
Group type: EXPERIMENTAL
Intervention: Bapineuzumab (0.5 mg/kg)
Number of subjects: 694
Study 27334799 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Bapineuzumab 0.5 mg/kg (noncarriers)
Number of subjects: 694
Study 27334799 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Bapineuzumab 1.0 mg/kg (noncarriers)
Number of subjects: 694
Study 27334799 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Bapineuzumab (0.5 mg/kg)
Number of subjects: 694
Study 27334799 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Bapineuzumab (1.0 mg/kg)
Number of subjects: 694
Study 24554074 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid CAS and coronary bypass surgery (Group 1)
Number of subjects: 20
Study 24554074 — intervention group
Group type: COMPARATOR
Intervention: Concomitant carotid and coronary surgery (Group 2)
Number of subjects: 20
Study 24554074 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 23075680 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed combined with cisplatin (PP group)
Number of subjects: 251
Study 23075680 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine combined with cisplatin (GP group)
Number of subjects: 251
Study 19861383 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive culture from generator pocket
Number of subjects: 122
Study 19861383 — intervention group
Group type: COMPARATOR
Intervention: Negative culture from generator pocket
Number of subjects: 122
Study 16714366 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet group received health and health‐behavior assessment, tailored feedback on health and health behavior (specifically fruit consumption), and an online referral to see a physician/nurse if necessary.
Number of subjects: 1071
Study 16714366 — intervention group
Group type: COMPARATOR
Intervention: P&P group received the same assessment, preprinted generic advice on fruit consumption and a mailed referral (where applicable).
Number of subjects: 1071
Study 16253185 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face guidance in early healthcare for children at home with a pamphlet developed by WHO as teaching material
Number of subjects: 100
Study 16253185 — intervention group
Group type: COMPARATOR
Intervention: Control group without receiving guidance
Number of subjects: 100
Study 16253185 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face guidance in early healthcare for children at home
Number of subjects: 100
Study 11911557 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day gatifloxacin 400 mg once daily
Number of subjects: 445
Study 11911557 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day gatifloxacin 400 mg once daily
Number of subjects: 445
Study 11911557 — intervention group
Group type: COMPARATOR
Intervention: 10-day amoxicillin/clavulanate 875 mg twice daily
Number of subjects: 445
Study 10419989 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark green, leafy vegetables with fat (10 g/100 g)
Number of subjects: 519
Study 7869865 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative management; details on dosage and duration not specified.
Number of subjects: 0
Study 7869865 — intervention group
Group type: COMPARATOR
Intervention: Surgery; details on dosage and duration not specified.
Number of subjects: 0
Study 2073672 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg q.p.m. (doubled if LDL > 140 mg/dl after 6 weeks)
Number of subjects: 184
Study 2073672 — intervention group
Group type: COMPARATOR
Intervention: Fenofibrate 200 mg b.i.d.
Number of subjects: 184
Study 2073672 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 184
Study 6459256 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine (5-Chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadiazole), administered t.i.d. for 7 days
Number of subjects: 20
Study 6459256 — intervention group
Group type: COMPARATOR
Intervention: Diazepam, administered t.i.d. for 7 days
Number of subjects: 20
Study 31870334 — intervention group
Group type: EXPERIMENTAL
Intervention: Village-based intervention (Pneumonia Awareness Sessions conducted by community health workers)
Number of subjects: 812
Study 31870334 — intervention group
Group type: EXPERIMENTAL
Intervention: Facility-based intervention (Pneumonia Awareness Sessions conducted by community health workers)
Number of subjects: 812
Study 29067761 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapies that improve outcomes in heart failure with reduced ejection fraction (HFrEF)
Number of subjects: 0
Study 25733635 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flavanone (305 mg) 100% orange juice
Number of subjects: 37
Study 25733635 — intervention group
Group type: COMPARATOR
Intervention: Low-flavanone (37 mg) orange-flavored cordial (500 mL)
Number of subjects: 37
Study 25122819 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized CRC risk information (prepared by a research assistant)
Number of subjects: 210
Study 25122819 — intervention group
Group type: COMPARATOR
Intervention: Standard CRC screening handout
Number of subjects: 210
Study 25122819 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized CRC risk information
Number of subjects: 210
Study 23032168 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningococcal ACWY-tetanus toxoid conjugate vaccine (ACWY-TT group; n = 231)
Number of subjects: 309
Study 23032168 — intervention group
Group type: COMPARATOR
Intervention: Licensed meningococcal ACWY polysaccharide vaccine (Men-PS group; n = 78)
Number of subjects: 309
Study 18435692 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological characteristics assessed by a self-administered questionnaire
Number of subjects: 1430
Study 17148749 — intervention group
Group type: EXPERIMENTAL
Intervention: PYY(3‐36) (0.8 pmol x kg(‐1) x min(‐1))
Number of subjects: 24
Study 17148749 — intervention group
Group type: EXPERIMENTAL
Intervention: PYY(3‐36) (0.2 pmol x kg(‐1) x min(‐1))
Number of subjects: 24
Study 17148749 — intervention group
Group type: EXPERIMENTAL
Intervention: PYY(1‐36) (1.6 pmol x kg(‐1) x min(‐1))
Number of subjects: 24
Study 17148749 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 24
Study 16194338 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustable oblique position
Number of subjects: 128
Study 16194338 — intervention group
Group type: COMPARATOR
Intervention: Prone position
Number of subjects: 128
Study 12381039 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual-reality (VR) treatment
Number of subjects: 20
Study 12381039 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral psychonutritional groups (Control)
Number of subjects: 20
Study 10541760 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg/day) plus calcium (1000 mg/day)
Number of subjects: 100
Study 10541760 — intervention group
Group type: COMPARATOR
Intervention: Calcium alone
Number of subjects: 100
Study 10541760 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate in high turnover (HT) patients
Number of subjects: 100
Study 10541760 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate in low turnover (LT) patients
Number of subjects: 100
Study 7762531 — intervention group
Group type: EXPERIMENTAL
Intervention: Arabica coffee oil (2 g daily)
Number of subjects: 36
Study 7762531 — intervention group
Group type: EXPERIMENTAL
Intervention: Robusta coffee oil (2 g daily)
Number of subjects: 36
Study 2191751 — intervention group
Group type: COMPARATOR
Intervention: Prepacol
Number of subjects: 100
Study 2191751 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole gut irrigation
Number of subjects: 100
Study 277749 — intervention group
Group type: EXPERIMENTAL
Intervention: DAT (Daunomycin, cytosine arabinoside, and 6-thioguanine)
Number of subjects: 100
Study 277749 — intervention group
Group type: COMPARATOR
Intervention: VAT (Vincristine, cytosine arabinoside, and 6-thioguanine)
Number of subjects: 100
Study 277749 — intervention group
Group type: EXPERIMENTAL
Intervention: DAT
Number of subjects: 100
Study 277749 — intervention group
Group type: COMPARATOR
Intervention: VAT
Number of subjects: 100
Study 277749 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DAT and VAT
Number of subjects: 100
Study 29498061 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritionally optimized default menu
Number of subjects: 127
Study 29498061 — intervention group
Group type: COMPARATOR
Intervention: Standard menu (suboptimal default)
Number of subjects: 127
Study 27430755 — intervention group
Group type: EXPERIMENTAL
Intervention: Ancient peat and apple extract (TRT)
Number of subjects: 25
Study 27430755 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 25
Study 25421252 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine alone (500-825 mg/m2/bid, days 1-21)
Number of subjects: 86
Study 25421252 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine plus Valproic acid (oral daily, day -14 to 21, target serum level 50-100 microg/ml)
Number of subjects: 86
Study 25421252 — intervention group
Group type: COMPARATOR
Intervention: Short-course radiotherapy (SCRT) (5 fractions of 5 Gy, days 1-5)
Number of subjects: 86
Study 22905926 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney disease (KD)
Number of subjects: 2642
Study 22905926 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal impairment (RI)
Number of subjects: 2642
Study 22905926 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuminuria
Number of subjects: 2642
Study 22905926 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic nephropathy (DN)
Number of subjects: 2642
Study 22905926 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuminuria without RI
Number of subjects: 2642